RubrYc Therapeutics Announces a Research Collaboration and License Option Agreement With Zai Labs
SAN CARLOS, Calif.–(BUSINESS WIRE)–Apr. 14, 2021 RubrYc Therapeutics, Inc., a pre-clinical biotherapeutics company developing epitope selective therapies, today announced that[…]
Read more